Cargando…
Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
Cystic fibrosis (CF) is a genetic disorder in which frequent pulmonary infections develop secondarily. One of the major pulmonary pathogens colonizing the respiratory tract of CF patients and causing chronic airway infections is Pseudomonas aeruginosa. Although tobramycin was initially effective aga...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620626/ https://www.ncbi.nlm.nih.gov/pubmed/28672861 http://dx.doi.org/10.3390/microorganisms5030035 |
_version_ | 1783267627397808128 |
---|---|
author | Sans-Serramitjana, Eulalia Jorba, Marta Fusté, Ester Pedraz, José Luis Vinuesa, Teresa Viñas, Miguel |
author_facet | Sans-Serramitjana, Eulalia Jorba, Marta Fusté, Ester Pedraz, José Luis Vinuesa, Teresa Viñas, Miguel |
author_sort | Sans-Serramitjana, Eulalia |
collection | PubMed |
description | Cystic fibrosis (CF) is a genetic disorder in which frequent pulmonary infections develop secondarily. One of the major pulmonary pathogens colonizing the respiratory tract of CF patients and causing chronic airway infections is Pseudomonas aeruginosa. Although tobramycin was initially effective against P. aeruginosa, tobramycin-resistant strains have emerged. Among the strategies for overcoming resistance to tobramycin and other antibiotics is encapsulation of the drugs in nanoparticles. In this study, we explored the antimicrobial activity of nanoencapsulated tobramycin, both in solid lipid nanoparticles (SLN) and in nanostructured lipid carriers (NLC), against clinical isolates of P. aeruginosa obtained from CF patients. We also investigated the efficacy of these formulations in biofilm eradication. In both experiments, the activities of SLN and NLC were compared with that of free tobramycin. The susceptibility of planktonic bacteria was determined using the broth microdilution method and by plotting bacterial growth. The minimal biofilm eradication concentration (MBEC) was determined to assess the efficacy of the different tobramycin formulations against biofilms. The activity of tobramycin-loaded SLN was less than that of either tobramycin-loaded NLC or free tobramycin. The minimum inhibitory concentration (MIC) and MBEC of nanoencapsulated tobramycin were slightly lower (1–2 logs) than the corresponding values of the free drug when determined in tobramycin-susceptible isolates. However, in tobramycin-resistant strains, the MIC and MBEC did not differ between either encapsulated form and free tobramycin. Our results demonstrate the efficacy of nanoencapsulated formulations in killing susceptible P. aeruginosa from CF and from other patients. |
format | Online Article Text |
id | pubmed-5620626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56206262017-10-03 Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas Sans-Serramitjana, Eulalia Jorba, Marta Fusté, Ester Pedraz, José Luis Vinuesa, Teresa Viñas, Miguel Microorganisms Article Cystic fibrosis (CF) is a genetic disorder in which frequent pulmonary infections develop secondarily. One of the major pulmonary pathogens colonizing the respiratory tract of CF patients and causing chronic airway infections is Pseudomonas aeruginosa. Although tobramycin was initially effective against P. aeruginosa, tobramycin-resistant strains have emerged. Among the strategies for overcoming resistance to tobramycin and other antibiotics is encapsulation of the drugs in nanoparticles. In this study, we explored the antimicrobial activity of nanoencapsulated tobramycin, both in solid lipid nanoparticles (SLN) and in nanostructured lipid carriers (NLC), against clinical isolates of P. aeruginosa obtained from CF patients. We also investigated the efficacy of these formulations in biofilm eradication. In both experiments, the activities of SLN and NLC were compared with that of free tobramycin. The susceptibility of planktonic bacteria was determined using the broth microdilution method and by plotting bacterial growth. The minimal biofilm eradication concentration (MBEC) was determined to assess the efficacy of the different tobramycin formulations against biofilms. The activity of tobramycin-loaded SLN was less than that of either tobramycin-loaded NLC or free tobramycin. The minimum inhibitory concentration (MIC) and MBEC of nanoencapsulated tobramycin were slightly lower (1–2 logs) than the corresponding values of the free drug when determined in tobramycin-susceptible isolates. However, in tobramycin-resistant strains, the MIC and MBEC did not differ between either encapsulated form and free tobramycin. Our results demonstrate the efficacy of nanoencapsulated formulations in killing susceptible P. aeruginosa from CF and from other patients. MDPI 2017-06-26 /pmc/articles/PMC5620626/ /pubmed/28672861 http://dx.doi.org/10.3390/microorganisms5030035 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sans-Serramitjana, Eulalia Jorba, Marta Fusté, Ester Pedraz, José Luis Vinuesa, Teresa Viñas, Miguel Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas |
title | Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas |
title_full | Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas |
title_fullStr | Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas |
title_full_unstemmed | Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas |
title_short | Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas |
title_sort | free and nanoencapsulated tobramycin: effects on planktonic and biofilm forms of pseudomonas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620626/ https://www.ncbi.nlm.nih.gov/pubmed/28672861 http://dx.doi.org/10.3390/microorganisms5030035 |
work_keys_str_mv | AT sansserramitjanaeulalia freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas AT jorbamarta freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas AT fusteester freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas AT pedrazjoseluis freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas AT vinuesateresa freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas AT vinasmiguel freeandnanoencapsulatedtobramycineffectsonplanktonicandbiofilmformsofpseudomonas |